Afrezza vs Insulin human
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 1 Diabetes
Shared mechanism: Insulin · full Type 1 Diabetes pipeline
Afrezza
Marketed by MannKind Corporation and partners
NCT04974528 · Phase 3 · completed
The study randomized 230 children and adolescents to mealtime Afrezza or to rapid-acting insulin injections, each with basal insulin; treatment was open-label rather than blinded. The primary endpoint was non-inferiority on HbA1c change at week 26, with a margin of 0.4 percentage points. The FDA label gives a difference of 0.18 percentage points (95% CI -0.07 to 0.44) and states that the primary endpoint of non-inferiority was not met. The figures are from the FDA label.
Next expected readout: March 2027 · NCT07224321 (registry estimate)
Reported efficacy
Change in HbA1c from baseline to week 26 (non-inferiority vs rapid-acting insulin analog, margin 0.4%): HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. (missed)
Result source: NCT04974528
Insulin human
Marketed by Eli Lilly
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Type 1 Diabetes
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Insulin human: no structured comparison results are available for Type 1 Diabetes.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Afrezza
show 1 more result
Available safety results
Afrezza
| Dropout rate | —Dose 1 NCT04849845 · Phase 4 · registry result, not featured evidence show 3 more results—Dose 2 NCT04849845 · Phase 4 · registry result, not featured evidence —2 x 15 U NCT00662857 · Phase 2 · registry result, not featured evidence —1 x 30 U NCT00662857 · Phase 2 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | —Dose 1 NCT04849845 · Phase 4 · registry result, not featured evidence show 3 more results—Dose 2 NCT04849845 · Phase 4 · registry result, not featured evidence —2 x 15 U NCT00662857 · Phase 2 · registry result, not featured evidence —1 x 30 U NCT00662857 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%Dose 1 NCT04849845 · Phase 4 · registry result, not featured evidence show 3 more results0%Dose 2 NCT04849845 · Phase 4 · registry result, not featured evidence 0%2 x 15 U NCT00662857 · Phase 2 · registry result, not featured evidence 0%1 x 30 U NCT00662857 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 3 more results2 x 15 U cough 14.8% headache 7.4% nausea 7.4% NCT00662857 · Phase 2 · registry result, not featured evidence 1 x 30 U cough 24.1% headache 17.2% hypoglycaemia 13.8% NCT00662857 · Phase 2 · registry result, not featured evidence |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Afrezza's landscape · Insulin human's landscape